- Home
- RIG vs TGTX Comparison
RIG vs TGTX Comparison
Compare RIG & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIG | TGTX |
|---|---|---|
| Founded | 1926 | 1993 |
| Country | Switzerland | United States |
| Employees | 5600 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 7.9B |
| IPO Year | 2008 | 2008 |
Fundamental Metrics
Financial Performance| Metric | RIG | TGTX |
|---|---|---|
| Price | $5.65 | $53.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $7.10 | ★ $49.80 |
| AVG Volume (30 Days) | ★ 38.7M | 1.8M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | ★ 0.21 | 0.17 |
| Revenue | ★ $2,973,000,000.00 | $2,785,000.00 |
| Revenue This Year | N/A | $49.08 |
| Revenue Next Year | N/A | $26.69 |
| P/E Ratio | ★ $27.19 | $321.47 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.03 | $26.76 |
| 52 Week High | $7.66 | $59.30 |
Technical Indicators
Market Signals| Indicator | RIG | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 53.83 |
| Support Level | $5.57 | $51.51 |
| Resistance Level | $6.14 | $58.04 |
| Average True Range (ATR) | 0.23 | 2.69 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 26.35 | 57.53 |
Price Performance
Historical ComparisonAbout RIG Transocean Ltd (Switzerland)
Transocean Ltd. is an international provider of offshore contract drilling services for oil and gas wells. The company provides mobile offshore drilling rigs, related equipment, and crews to support the drilling of oil and gas wells. Its fleet mainly consists of offshore rigs, including drillships, semisubmersibles, and jackups.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.